Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation

The REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe AD who had no prior treatment with biologic or ...

Why Your Team’s Executive Presentations Are Failing—And What To Do About It

Here are some key strategies you can use to help your teams develop the skills needed to excel as executive-level presenters.
The New RepublicOpinion

How Political “Authenticity” Became Code for Masculinity

It’s a trait that’s too often defined by traditional gender expectations. Here’s how the latest generation of women in ...
KOMU 8

Columbia Airport Advisory Board hears presentation on MACC aviation program

COLUMBIA — The Columbia Airport Advisory Board heard the first presentation Wednesday about a program by Moberly Area ...

Deadline extended for AT&T class action settlement: How to file a claim

WASHINGTON — A judge has extended the deadline for AT&T customers to file a claim to be part of a $177 million settlement ...

The Mindset Shift I Teach at Harvard to Create Captivating Presentations

Most PowerPoints are boring because they don't follow a storytelling structure. Here's how to make your presentations memorable and effective.
WCBD

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and ...

KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 KT-621 Phase 2b trials in AD and asthma on track to initiate in 4Q25 and 1Q26, ...
Nasdaq

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and ...

KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 KT-621 Phase 2b trials in AD and asthma on track to initiate in 4Q25 and 1Q26, ...